Diagnostic performance of PIVKA-II in identifying recurrent hepatocellular carcinoma following curative resection: a retrospective cohort study
Open Access
- 10 April 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-9
Abstract
Protein induced by vitamin K absence or antagonist II (PIVKA-II) plays a critical role in the diagnosis of hepatocellular carcinoma (HCC), however, studies on its efficacy in diagnosing recurrent HCC were rarely found. A multicenter, retrospective, and observational study was conducted. During the overall follow-up of 5 years, HCC patients who had curative resection were monitored every 3 months in the first year post-surgery and every 6 months thereafter if no recurrence occurred. Tumor markers were collected at the diagnosis of recurrence for those with recurrence and at the last follow-up for those without recurrence. The median serum levels of PIVKA-II and AFP in the recurrence group were significantly higher than those in the non-recurrence group (PIVKA-II: 84.62 vs. 18.76 mAU/ml, p < 0.001; AFP: 4.90 vs. 3.00 ng/ml, p < 0.001) and there is a significant correlation between PIVKA-II and AFP (R = 0.901, p < 0.001). PIVKA-II showed better accuracy than AFP in the diagnosis of overall recurrent HCC (AUC: 0.883 vs. 0.672; p < 0.0001), but also in patients with negative PIVKA-II before curative resection (AUC: 0.878 vs. 0.680, p = 0.001). Clinician should pay more attention to serum PIVKA-II values when following patients after curative HCC resection to detect early recurrence.Clinical trial registration: ChiCTR2300070874Keywords
Funding Information
- National Natural Science Foundation of China (82100691, 82270688, 82070673)
This publication has 29 references indexed in Scilit:
- The Global Burden of Cancer 2013JAMA Oncology, 2015
- Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasionJournal of Hepatology, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Determinants of Serum Alpha-Fetoprotein Levels in Hepatitis C–Infected PatientsClinical Gastroenterology and Hepatology, 2012
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Des-γ-carboxy prothrombin stimulates human vascular endothelial cell growth and migrationClinical & Experimental Metastasis, 2009
- Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cellsLife Sciences, 2008
- Expansion of Selection Criteria for Patients with Hepatocellular Carcinoma in Living Donor Liver TransplantationLiver Transplantation, 2007
- Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomyJournal of Hepatology, 2003
- Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV statusJournal of Hepatology, 2001